Short Interest in Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Grows By 80.3%

Key Points

• Short interest in Shionogi & Co., Ltd. Unsponsored ADR surged by 80.3% in September, increasing from 25,900 shares to 46,700 shares.
• Despite the rise in short interest, the stock's average trading volume remained significantly lower, with a days-to-cover ratio of only 0.5 days.
• The company reported an earnings per share (EPS) of $0.16 for the last quarter, surpassing the consensus estimate of $0.14.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 46,700 shares, a growth of 80.3% from the September 15th total of 25,900 shares. Based on an average trading volume of 98,000 shares, the days-to-cover ratio is currently 0.5 days. Based on an average trading volume of 98,000 shares, the days-to-cover ratio is currently 0.5 days.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

Shares of SGIOY traded down $0.04 during mid-day trading on Tuesday, hitting $8.04. The company's stock had a trading volume of 24,138 shares, compared to its average volume of 100,873. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.13 and a current ratio of 6.63. The firm has a 50-day moving average price of $8.67 and a 200 day moving average price of $8.45. Shionogi & Co., Ltd. Unsponsored ADR has a fifty-two week low of $6.53 and a fifty-two week high of $9.23.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last released its earnings results on Monday, July 28th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. The business had revenue of $672.90 million for the quarter, compared to analyst estimates of $719.55 million. As a group, sell-side analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.